cagrilintide fda 5mg Peptide cagrilintide fda Novo Nordisk Submits

Cross-Trial: The Only Fair Comparisons This is the honesty centerpiece of the entire comparison

Fras JP, Davies MJ, Rosenstock J, et al

It does not show that cagrilintide monotherapy matches the CagriSema results the Phase 3 data belong to the combination with semaglutide, not to cagrilintide alone

It incorporates key modifications, including 14E/17R mutations to stabilize an -helical segment via a salt bridge, multiple proline substitutions (25P, 28P, 29P) to reduce -sheet formation, and N-terminal C20 fatty diacid lipidation for reversible albumin binding (Kruse et al

Its long-term safety is simply not yet established, because it remains investigational

References Lau DCW, Erichsen L, Francisco AM, et al